Coagulation disorders in acute lung injury

Current Respiratory Medicine Reviews

Volumn 5, Issue 3, 2009, Pages 149-159

  Adda, Mélanie ^a   Ferrer, Ricard ^a   Puig, Ferranda ^a   Crespo, Javier ^b   Artigas, Antoni ^a  

^a HOSPITAL DE SABADELL   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Activated protein C; Acute lung injury; Acute respiratory distress syndrome; Coagulation disorders

Indexed keywords

ACTIVATED PROTEIN C; ALT 836; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 7A; CAPTOPRIL; COLLAGEN; CORTICOSTEROID; DROTRECOGIN; FIBRIN; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; LOSARTAN; PLACEBO; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN ANTIBODY; PROTEINASE ACTIVATED RECEPTOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TM 5007; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CELL AGGREGATION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE MODEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; EPITHELIUM CELL; FIBRIN DEPOSITION; FIBRINOLYSIS; HEALTH CARE COST; HUMAN; HYPOXEMIA; INTENSIVE CARE UNIT; LOW DRUG DOSE; LUNG ALVEOLUS; LUNG ALVEOLUS MACROPHAGE; LUNG EDEMA; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG INFILTRATE; LUNG INTERSTITIUM; LUNG LAVAGE; MEDIATOR RELEASE; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MORBIDITY; MORTALITY; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR BINDING; REVIEW; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; THORAX RADIOGRAPHY; TIDAL VOLUME; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 74849123665     PISSN: 1573398X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339809788922342     Document Type: Review

References (126)

1. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-24.
2. Esteban A, Fernández-Segoviano P, Frutos-Vivar F, et al. Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy findings. Ann Intern Med 2004; 141(6): 440-5.
3. Ferguson ND, Frutos-Vivar F, Esteban A, et al. Acute respiratory distress syndrome: underrecognition by clinicians and diagnostic accuracy of three clinical definitions. Crit Care Med 2005; 33(10): 2228-34.
4. Villar J, Pérez-Méndez L, López J, et al. HELP Network. An early PEEP/FIO2 trial identifies different degrees of lung injury in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2007; 176(8): 795-804.
5. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353(16): 1685-93.
6. Malhotra A. Low-tidal-volume ventilation in the acute respiratory distress syndrome. N Engl J Med 2007; 357(11): 1113-20.
7. Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest 2008; 133(5): 1120-7.
8. Phua J, Badia JR, Adhikari NK, et al. Has mortality from acute respiratory distress syndrome decreased over time? A systematic review. Am J Respir Crit Care Med 2009; 179(3): 220-7.
9. Ferrer R, Bauer T, Torres T. Nosocomial pneumonia during acute respiratory distress syndrome. Clin Intensive Care 2001; 12(2): 43-51.
10. Tremblay LN, Slutsky AS. Ventilator-induced lung injury: from the bench to the bedside. Intensive Care Med 2006; 32(1): 24-33.
11. Oeckler RA, Hubmayr RD. Ventilator-associated lung injury: a search for better therapeutic targets. Eur Respir J 2007; 30(6): 1216-26.
12. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342(18): 1301-8.
13. Sakr Y, Vincent JL, Reinhart K, et al. High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest 2005; 128(5): 3098-108.
14. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354(24): 2564-75.
15. Hudson L, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151: 293-301.
16. Altemeier WA, Matute-Bello G, Frevert CW, et al. Mechanical ventilation with moderate tidal volumes synergistically increases lung cytokine response to systemic endotoxin. Am J Physiol Lung Cell Mol Physiol 2004; 287(3): L533-42.
17. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342(18): 1334-49.
18. Gunther A, Mosavi P, Heinemann S, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161(2 Pt 1): 454-62.
19. Ware LB, Camerer E, Welty-Wolf K, Schultz MJ, Matthay MA. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2006; 291(3): L307-11.
20. Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982; 3(1): 35-56.
21. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003; 31(4 Suppl): S213-20.
22. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000; 22(4): 401-4.
23. Finigan JH. The coagulation system and pulmonary endothelial function in acute lung injury. Microvasc Res 2009; 77(1): 35-8.
24. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344(10): 699-709.
25. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia - a review. Crit Care Med 2006; 34(3): 871-7.
26. Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178(6): 618-23.
27. Rubenfeld GD, Abraham E. When is a negative phase II trial truly negative? Am J Respir Crit Care Med 2008; 178(6): 554-5.
28. Goodman RB, Pugin J, Lee JS, Matthay MA. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev 2003; 14(6): 523-35.
29. Pugin J, Verghese G, Widmer MC, Matthay MA. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit Care Med 1999; 27(2): 304-12.
30. Park WY, Goodman RB, Steinberg KP, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164(10 Pt 1): 1896-903.
31. Millo JL, Schultz MJ, Williams C, et al. Compartmentalisation of cytokines and cytokine inhibitors in ventilated-associated pneumonia. Int Care Med 2004; 30: 68-74.
32. Choi G, Schultz MJ, van Till JW, et al. Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004; 24(5): 786-9.
33. van Till JW, Levi M, Bresser P, Schultz MJ, Gouma DJ, Boermeester MA. Early procoagulant shift in the bronchoalveolar compartment of patients with secondary peritonitis. J Infect Dis 2006; 194(9): 1331-9.
34. Idell S, James KK, Levin EG, et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84(2): 695-705.
35. Wang L, Bastarache JA, Wickersham N, Fang X, Matthay MA, Ware LB. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol 2007; 36(4): 497-503.
36. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109(22): 2698-704.
37. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285(3): L514-21.
38. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345(6): 408-16.
39. Bastarache JA, Wang L, Wang Z, Albertine KH, Matthay MA, Ware LB. Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol 2008; 294(5): L874-81.
40. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285(1): L20-8.
41. Bertozzi P, Astedt B, Zenzius L, et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990; 322(13): 890-897.
42. Chen CM, Chou HC, Wang LF, Lang YD. Captopril decreases plasminogen activator inhibitor-1 in rats with ventilator-induced lung injury. Crit Care Med 2008; 36(6): 1880-5.
43. Wösten-van Asperen RM, Lutter R, Haitsma JJ, et al. ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin. Eur Respir J 2008; 31(2): 363-71.
44. Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991; 261(4 Pt 1): L240-L8.
45. Fuchs-Buder T, de Moerloose P, Ricou B, et al. Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153(1): 163-7.
46. Rowland FN, Donovan MJ, Picciano PT, Wilner GD, Kreutzer DL. Fibrin-mediated vascular injury. Identification of fibrin peptides that mediate endothelial cell retraction. Am J Pathol 1984; 117(3): 418-28.
47. Marshall R, Bellingan G, Laurent G. The acute respiratory distress syndrome: fibrosis in the fast lane. Thorax 1998; 53(10): 815-7.
48. Seeger W, Grube C, Gunther A. Proteolytic cleavage of fibrinogen: amplification of its surfactant inhibitory capacity. Am J Respir Cell Mol Biol 1993; 9(3): 239-47.
49. Gray AJ, Bishop JE, Reeves JT, Mecham RP, Laurent GJ. Partially degraded fibrin(ogen) stimulates fibroblast proliferation in vitro. Am J Respir Cell Mol Biol 1995; 12(6): 684-90.
50. Fukuda Y, Ishizaki M, Masuda Y, Kimura G, Kawanami O, Masugi Y. The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol 1987; 126(1): 171-82.
51. Zapol WM, Jones R. Vascular components of ARDS. Clinical pulmonary hemodynamics and morphology. Am Rev Respir Dis 1987; 136: 471-4.
52. Greene R. Pulmonary vascular obstruction in the adult respiratory distress syndrome. J Thorac Imaging 1986; 1(3): 31-8.
53. Nuckton TJ, Alonso JA, Kallet RH, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med 2002; 346(17): 1281-6.
54. Stevens T, Garcia JG, Shasby DM, Bhattacharya J, Malik AB. Mechanisms regulating endothelial cell barrier function. Am J Physiol Lung Cell Mol Physiol 2000; 279(3): L419-L22.
55. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407(6801): 258-64.
56. Trepat X, Grabulosa M, Buscemi L, Rico F, Farre R, Navajas D. Thrombin and histamine induce stiffening of alveolar epithelial cells. J Appl Physiol 2005; 98(4): 1567-74.
57. Artigas A, Puig F, Adda M, Marti-Sistac O, Navajas D, Farré R. Effect of activated protein C on cell contraction of human alveolar epithelial cells subjected to thrombin. 21st European Society of Intensive Care Medicine (ESCIM), Lisbon, Portugal. Intensive Care Med 2008; 34: S52.
58. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32(Suppl 1): 49-60.
59. Levi M, van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007; 11 (Suppl 5): S3.
60. Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost 2006; 32(1): 24-32.
61. Barazzone C, Belin D, Piguet PF, Vassalli JD, Sappino AP. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J Clin Invest 1996; 98(12): 2666-73.
62. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97(1): 232-7.
63. Kwak SH, Wang XQ, He Q, et al. Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway. Thromb Haemost 2006; 95(5): 829-35.
64. Park YJ, Liu G, Lorne EF, et al. PAI-1 inhibits neutrophil efferocytosis. Proc Natl Acad Sci USA 2008; 105(33): 11784-9.
65. Park YJ, Liu G, Tsuruta Y, Lorne E, Abraham E. Participation of the urokinase receptor in neutrophil efferocytosis. Blood 2009 [Epub ahead of print].
66. Wang XQ, Bdeir K, Yarovoi S, Cines DB, Fang W, Abraham E. Involvement of the urokinase kringle domain in lipopolysaccharide-induced acute lung injury. J Immunol 2006; 177(8): 5550-7.
67. Idell S, Kumar A, Zwieb C, Holiday D, Koenig KB, Johnson AR. Effects of TGF-beta and TNF-alpha on procoagulant and fibrinolytic pathways of human tracheal epithelial cells. Am J Physiol 1994; 267(6 Pt 1): L693-L703.
68. Idell S. Extravascular coagulation and fibrin deposition in acute lung injury. New Horiz 1994; 2(4): 566-74.
69. Gaggar A, Olman MA. Biologic markers of mortality in acute lung injury. Clin Chim Acta 2006; 372(1-2): 24-32.
70. Ware LB. Prognostic determinants of acute respiratory distress syndrome in adults: impact on clinical trial design. Crit Care Med 2005; 33(3 Suppl): S217-22.
71. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35(8): 1821-8.
72. McClintock D, Zhuo H, Wickersham N, Matthay MA, Ware LB. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care 2008; 12(2): R41.
73. Knoebl PN. Is there an association between hemostatic abnormalities and the outcome of acute lung injury? Crit Care Med 2007; 35(8): 1980-2.
74. Ferring M, Vincent JL. Is outcome from ARDS related to the severity of respiratory failure? Eur Respir J 1997; 10(6): 1297-300.
75. Laterre PF, Wittebole X, Dhainaut JF. Anticoagulant therapy in acute lung injury. Crit Care Med 2003; 31(Suppl 4): S329-S36.
76. Ferrer R, Adda M, Navas A, Pasini M, Artigas A. Blood coagulation and inflammation in acute lung injury. J Organ Dysfunc 2009; 5(2): 101-9.
77. Hofstra JJ, Juffermans NP, Schultz MJ, Zweers MM. Pulmonary coagulopathy as a new target in lung injury - a review of available pre-clinical models. Curr Med Chem 2008; 15(6): 588-95.
78. Choi G, Vlaar AP, Schouten M, et al. Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J 2007; 30(3): 423-8.
79. Hofstra JJ, Haitsma JJ, Juffermans NP, Levi M, Schultz MJ. The role of bronchoalveolar hemostasis in the pathogenesis of acute lung injury. Semin Thromb Hemost 2008; 34(5): 475-84.
80. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88(6): 2093-100.
81. Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003; 102(4): 1499-505.
82. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105(8): 3178-84.
83. Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280(17): 17286-93.
84. Zeng W, Matter WF, Yan SB, Um SL, Vlahos CJ, Liu L. Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit Care Med 2004; 32(5 Suppl): S302-8.
85. Finigan JH, Boueiz A, Wilkinson E, et al. Activated protein C protects against ventilator-induced pulmonary capillary leak. Am J Physiol Lung Cell Mol Physiol 2009, 296(6): L1002-11.
86. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9(3): 338-42.
87. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109(8): 3161-72.
88. Gupta A, Gerlitz B, Richardson MA, et al. Distinct functions of activated protein C differentially attenuate acute kidney injury. J Am Soc Nephrol 2009; 20(2): 267-77.
89. van der Poll T, Levi M, Nick JA, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005; 171(10): 1125-1128.
90. Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104(13): 3878-85.
91. Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31(3): 834-40.
92. Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33(5): 952-61.
93. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36(1): 296-327.
94. Abraham E, Laterre PF, Garg R, et al. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353(13): 1332-41.
95. Nadel S, Goldstein B, Williams MD, et al; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369(9564): 836-43.
96. Finfer S, Ranieri VM, Thompson BT, et al. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008; 34(11): 1935-47.
97. Wood KA, Huang D, Angus DC. Improving clinical trial design in acute lung injury. Crit Care Med 2003; 31(4 Suppl): S305-11.
98. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29(11): 2081-9.
99. Abraham E, Reinhart K, Opal S, et al; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290(2): 238-47.
100. Laterre PF. Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition. Crit Care 2008; 12(Suppl 6): S4.
101. Laterre PF, Opal SM, Abraham E, et al. A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care 2009; 13(2): R36.
102. Vincent JL, Artigas A, Petersen LC, Meyer C. A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome. Crit Care Med 2009; 37(6): 1874-80.
103. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286(15): 1869-78.
104. Zarychanski R, Doucette S, Fergusson D, et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008; 36(11): 2973-9.
105. Jaimes F, De La Rosa G, Morales C, et al. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med 2009; 37(4): 1185-96.
106. Stringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic Biol Med 1998; 25(2): 184-8.
107. Hardaway RM, Williams CH, Marvasti M, et al. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med 1990; 18(12): 1413-8.
108. Greene R, Lind S, Jantsch H, et al. Pulmonary vascular obstruction in severe ARDS: angiographic alterations after i.v. fibrinolytic therapy. Am J Roentgenol 1987; 148(3): 501-8.
109. Hardaway RM, Harke H, Tyroch AH, Williams CH, Vazquez Y, Krause GF. Treatment of severe acute respiratory distress syndrome: a final report on a phase I study. Am Surg 2001; 67(4): 377-82.
110. Esmon CT, Ding W, Yasuhiro K, et al. The protein C pathway: new insights. Thromb Haemost 1997; 78(1): 70-4.
111. Van de Wouwer M, Conway EM. Novel functions of thrombomodulin in inflammation. Crit Care Med 2004; 32(5 Suppl): S254-61.
112. Izuhara Y, Takahashi S, Nangaku M, et al. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol 2008; 28(4): 672-7.
113. Gunther A, Lubke N, Ermert M, et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003; 168(11): 1358-65.
114. Yasui H, Gabazza EC, Tamaki S, et al. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 2001; 163(7): 1660-8.
115. Slofstra SH, Groot AP, Maris NA, Reitsma PH, Cate HT, Spek CA. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol 2006; 149(6): 740-6.
116. Dixon B, Santamaria JD, Campbell DJ. A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 2008; 12(3): R64.
117. Rice TW, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: challenges in clinical trial design. Clin Chest Med 2006; 27(4): 733-54.
118. Phua J, Stewart TE, Ferguson ND. Acute respiratory distress syndrome 40 years later: time to revisit its definition. Crit Care Med 2008; 36(10): 2912-21.
119. Abraham E, Baughman R, Fletcher E, et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med 1999; 27(8): 1478-85.
120. No authors listed. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002; 30(1): 1-6.
121. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med 1996; 334(22): 1417-21.
122. Gattinoni L, Tognoni G, Pesenti A, et al; Prone-Supine Study Group. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 2001; 345(8): 568-73.
123. Taylor RW, Zimmerman JL, Dellinger RP, et al; Inhaled Nitric Oxide in ARDS Study Group. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004; 291(13): 1603-9.
124. No authors listed. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. JAMA 2000; 283(15): 1995-2002.
125. Santos C, Ferrer M, Roca J, Torres A, Hernández C, Rodriguez-Roisin R. Pulmonary gas exchange response to oxygen breathing in acute lung injury. Am J Respir Crit Care Med 2000; 161(1): 26-31.
126. Eichacker PQ, Parent C, Kalil A, et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166(9): 1197-205.